HR 5402
116th Congress
House
Taxation
Drug safety, medical device, and laboratory regulation
Drug therapy
Government studies and investigations
Income tax credits
Medical research
Protecting America’s Life Saving Medicines Act of 2019
Introduced: December 11, 2019
Introduced by:
Gottheimer, Josh
Democratic
· New Jersey
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 12, 2019
Referred to the Subcommittee on Health.
Dec 11, 2019
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dec 11, 2019
Introduced in House
Plain-English summary
Protecting America's Life Saving Medicines Act of 2019
This bill directs the Food and Drug Administration (FDA) to conduct a study on drugs that are currently being tested and are unlikely to be approved, but would, if approved, address an unmet medical need for the treatment of a serious or life threatening disease or condition or a rare disease or condition (high-risk, high-reward drugs). The FDA must submit to the Department of the Treasury a list of such high-risk, high-reward drugs not later than 180 days after the completion of the study.
The bill also allows a new tax credit for 25% of the clinical testing expenses for high-risk, high-reward drugs.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
3
Cosponsors
1